Clinical lymphoma, myeloma & leukemia · 2026
Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Cheryl H, Taylor Allison O, Mitchell Nia M, Locke Susan C, Troy Jesse D, Bystrom Rebecca P, Erba Harry P, Hong Sanghee, Lin Chenyu, LeBlanc Thomas W
Аннотация
BACKGROUND: VIALE-A established azacitidine and venetoclax as first-line therapy for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. However, real-world use of venetoclax often differs from clinical trial protocols.
PATIENTS AND METHODS: We conducted a single-center retrospective study of 160 AML patients treated with first-line venetoclax-based therapy to investigate how cycle 1 venetoclax exposure, characterized by treatment duration and dose (adjusted for CYP3A inhibitor use), is associated with treatment outcomes.
RESULTS: The composite complete response (CRc) rate was 55% overall, and 66% among patients with an evaluable bone marrow biopsy, with a median time to CRc of 41.5 days. Patients receiving 21 ± 3 days of venetoclax in cycle 1 demonstrated higher CRc rates and shorter time to CRc compared with those receiving the standard 28 days, while greater venetoclax dose or exposure in cycle 1 was not associated with improved outcomes. Hematologic adverse events requiring treatment modification were significantly associated with the achievement of CRc (P < .001). Cycle 1 venetoclax exposure did not correlate with subsequent treatment duration.
CONCLUSION: These findings suggest that increased early venetoclax exposure was not associated with improved clinical outcomes in this real-world cohort; however, prospective studies are needed to validate these observations and inform optimization of venetoclax dosing strategies in real-world practice.
PATIENTS AND METHODS: We conducted a single-center retrospective study of 160 AML patients treated with first-line venetoclax-based therapy to investigate how cycle 1 venetoclax exposure, characterized by treatment duration and dose (adjusted for CYP3A inhibitor use), is associated with treatment outcomes.
RESULTS: The composite complete response (CRc) rate was 55% overall, and 66% among patients with an evaluable bone marrow biopsy, with a median time to CRc of 41.5 days. Patients receiving 21 ± 3 days of venetoclax in cycle 1 demonstrated higher CRc rates and shorter time to CRc compared with those receiving the standard 28 days, while greater venetoclax dose or exposure in cycle 1 was not associated with improved outcomes. Hematologic adverse events requiring treatment modification were significantly associated with the achievement of CRc (P < .001). Cycle 1 venetoclax exposure did not correlate with subsequent treatment duration.
CONCLUSION: These findings suggest that increased early venetoclax exposure was not associated with improved clinical outcomes in this real-world cohort; however, prospective studies are needed to validate these observations and inform optimization of venetoclax dosing strategies in real-world practice.